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Clinical evaluation of recombinant human 
platelet-derived growth factor for the 
treatment of lower extremity diabetic ulcers 
David L. Steed, MD, and the Diabetic Ulcer Study Group, ~ Pittsburgh, Pa. 
Purpose: The purpose of this study was to investigate he efficacy and safety of recombi- 
nant human platelet-derived growth factor (rhPDGF-BB) in a double-blind, placebo- 
controlled, multicenter study of patients with chronic diabetic ulcers. 
Methods: Patients with chronic, full-thickness, lower-extremity diabetic neurotrophic 
ulcers of at least 8 weeks' duration, free of necrotic and infected tissue after debridement, 
and with transcutaneous oxygen tensions of 30 mm Hg or greater were studied. A total 
of 118 patients were randomized toreceive ither topical rhPDGF-BB (2.2 lxg/cm 2 of ulcer 
area) or placebo until the ulcer was completely resurfaced or for a maximum of 20 weeks, 
whichever occurred first. 
Results: Twenty-nine (48%) of 61 patients randomized tothe rhPDGF-BB group achieved 
complete wound healing during the study compared with only 14 (25%) of 57 patients 
randomized tothe:placebo group (p = 0.01). The median reduction in wound area in the 
group given rhPDGF-BB was 98.8% compared with 82.1% in the group given placebo 
(p = 0.09). There were no significant differences in the incidence or severity of adverse 
events between the rhPDGF-BB and placebo groups. 
Conclusions: Once-daily topical application f rhPDGF-BB is safe and effective in 
stimulating the healing of chronic, full-thickness, lower-extremity diabetic neurotrophic 
ulcers. (J VASe SURG 1995;21:71-81.) 
Chronic nonhealing ulcers of the lower extremity 
are an important problem for patients with diabetes 
mellitus. These ulcers develop in diabetic patients as 
a result of multiple factors that include peripheral 
neuropathy, local trauma, and ischemia. 1 The stan- 
dard treatments for such ulcers include mechanical 
debridement, reatment of infection, avoidance of 
weight bearing on the affected area, and revascular- 
ization of ischemic regions. 2 However, failure of 
wound healing may occur with these treatments, 
even when the initiating causes are removed. Failure 
of wound healing may result in an increased incidence 
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of infection and gangrene and may even lead to 
amputations. 2 
Several growth factors have been identified 
that play a role in wound healing, s,4 These in- 
clude platelet-derived growth factor (PDGF), epider- 
mal growth factor (EGF), fibroblast growth factors, 
transforming growth factors, and insulin-like growth 
factor. PDGF is a protein with a molecular weight of 
30,000 daltons  that is normally secreted by platelets, 
macrophages, endothelial cells, and, under certain 
conditions, fibroblasts. 6 PDGF promotes avariety of 
activities in fibroblasts, smooth muscle cells, and 
capillary endothelial cells including cell mitogenesis 
and migration and synthesis of protein and extracel- 
lular matrix components. PDGF also induces cell 
chemotaxis and activation of inflammatory cel ls.  6 All 
of these cellular processes are important in wound 
healing. 
Naturally occurring PDGF is composed of two 
peptide chains (A and B) held together by intermo- 
lecular disulfide bonds; both heterodimeric and 
homodimeric forms coexist. 7 Two subunits of the 
PDGF receptor have been identified in responding 
cells and these are brought ogether by one of the 
isoforms of PDGF. 8 The PDGF-A chain preferen- 
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tially binds to the ~ receptor, whereas the PDGF-B 
chain binds to both the cx and 13 receptors. Different 
target cell types contain different concentrations of 
the two receptor subunits that give a basis for a 
degree of specificity of the three isoforms of PDGF 
(PDGF-AA, PDGF-BB, and PDGF-AB). 
A recombinant humari form ofPDGF (rhPDGF- 
BB, homodimer) has been produced from genetically 
engineered yeast cells, into which the gene for the 
B-chain of PDGF had been inserted. Animal studies 
have shown that rhPDGF-BB accelerates the wound- 
healing cascade by promoting the growth of granu- 
lation tissue. 9,1° In addition, a clinical pharmacoki- 
netic study of topically administered rhPDGF-BB in 
patients with pressure ulcers has shown the recom- 
binant product o be minimally absorbed into the 
systemic irculation (unpublished data). 
There are few reports on the topical use of 
rhPDGF-BB to stimulate wound healing in patients. 
Robson et al. n evaluated the effect of topical 
rhPDGF-BB on the healing of chronic pressure ulcers 
in a double-blind, placebo-controlled trial of 20 
patients. They showed that patients treated for 28 
days with rhPDGF-BB, i ~g/cm 2 ulcer area daily, 
had smaller ulcers than had placebo-treated patients, 
although lower doses of rhPDGF-BB were not 
effective. Mustoe et al. 12 evaluated the effect of 
rhPDGF-BB in a double-blind, placebo-controlled 
trial of 41 patients with deep pressure ulcers. At the 
end of 28 days of treatment, the ulcers were reduced 
in size in patients treated with 1 or 3 ~g/cm 2 
rhPDGF-BB compared with patients treated with 
placebo. 
In this article we report the results of a ran- 
domized, prospective, double-blind, parallel-group, 
placebo-controlled, multicenter clinical trial to 
evaluate the therapeutic efficacy and safety of 
rhPDGF-BB in stimulating the healing of chronic 
neurotrophic ulcers of the lower extremity in pa- 
tients with diabetes mellitus. To our knowledge, this 
is the first well-controlled, multicenter clinical trial 
of rhPDGF-BB in patients with diabetic ulcers. 
MATERIAL AND METHODS 
Patients. A total of 118 patients with chronic (of 
at least 8 weeks' duration), nonhealing, full-thickness, 
lower-extremity ulcers resulting from diabetes mel- 
litus were enrolled at 10 centers in the United States 
during a 15-month period. Each patient gave in- 
formed, written consent according to procedures 
approved by the institutional review board at each 
site. To be eligible for the trial, patients had to be at 
least 19 years of age with at least one ulcer of between 
1 and 100 cm 2 in surface area (length times width), 
determined to be free of infection by clinical exami- 
nation and x-ray films, if required, and with adequate 
arterial blood supply, assessed by measuring trans- 
cutaneous oxygen tensions (transcutaneous partial 
pressure of oxygen of 30 mm Hg or greater) on the 
dorsum of the foot or at the ulcer margin. 
Women of childbearing potential or nursing 
mothers were excluded from the trial. Other exclu- 
sion criteria included patients with evidence of 
hypersensitivity to any components ofthe study gel; 
patients with more than three ulcers; patients with 
ulcer wounds originating from large-vessel arterial 
insufficiency, venous insufficiency, pressure ulcers, or 
necrobiosis lipoidica diabeticorum; patients with 
osteomyelitis; malignant or terminal disease; known 
alcohol or drug abuse; use of any investigational drug 
or device within 30 days of admission; and evidence 
of thermal, electrical, or radiation burn wounds at the 
site of the target ulcer. Patients who were receiving 
corticosteroids, immunosuppressive agents, radia- 
tion therapy, or chemotherapy were also excluded. 
A standard physical examination was performed 
and full medical history was obtained on each patient 
before entry into the trial. Evaluations of transcuta- 
neous partial pressure of oxygen were performed 
with a system 800 transcutaneous monitoring 
system (Novametrix Medical Systems Inc., Walling- 
ford, Conn.). The presence of osteomyelitis was 
determined by physical examinations including prob- 
ing of the wound and plain x-ray films. Nine patients 
in each treatment group had previously undergone 
vascular reconstruction. Patients had to wait a 
minimum of 8 weeks after the surgery before they 
could enter the trial. 
Before randomization, the target ulcer was ag- 
gressively surgically debrided to remove all callus, 
necrotic tissue, and chronic granulation tissue. The 
initial debridement was performed 1 to 2 weeks 
before randomization. Further surgical debridements 
could be performed as required throughout he 
treatment period. 
Preparation of study drug. Lyophilized 
rhPDGF-BB, purified from genetically engineered 
yeast, was manufactured and supplied by Chiron 
Corp., Emeryville, Calif. The drug was formulated 
into a gel at a concentration of 30 ~g rhPDGF- 
BB/gm gel and packaged into 15 gm tubes by 
Johnson and Johnson (New Brunswick, N.J.). 
Matching placebo gel was packaged inidentical tubes 
and there Were no differences incolor, consistency, or
odor between the placebo and rhPDGF-BB gels. 
Randomization and treatment. Patients were 
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randomly assigned to treatment with either hPDGF- 
BB or placebo gel, according to a computer- 
generated randomization schedule for each center, 
prepared before study initiation, by RW Johnson 
Pharmaceutical Research Institute, Raritan, N.J. 
Baseline target ulcer measurements were taken at this 
time. 
A patient could have up to three ulcers at the time 
of randomization, but only the ulcer with the greatest 
surface area at initiation of the study, defined as the 
target ulcer, was evaluated, rhPDGF-BB gel or 
placebo gel was applied to the target ulcer every 24 
hours at a dose equivalent to approximately 2.2 txg 
rhPDGF-BB/cm 2 ulcer area for 20 weeks or until 
complete wound healing was achieved, whichever 
occurred first. The amount of gel applied to the target 
ulcer was determined at each visit and based on the 
target ulcer area. The gel was spread evenly over the 
entire ulcer surface. A nonadherent, saline-soaked 
gauze dressing was placed directly over the target 
ulcer and the foot was wrapped circumferentially 
with roll gauze immediately after gel was applied. 
The first gel and dressing application was performed 
at the study center and included instructions to the 
patient or care giver on proper wound care and gel 
and dressing changing procedures. Twelve hours 
later, the residual gel was removed by gentle irriga- 
tion with saline solution. A saline-moistened gauze 
dressing was then applied. All patients were followed 
up on an outpatient basis, with dressing changes 
performed by the patients or care givers. Further 
sharp debridements could be performed at each 
evaluation if the investigator considered them to be 
required. Other than the study gel, no products were 
allowed to be applied to the target ulcer. 
The investigator instructed the patient on the 
method of pressure relief at the target ulcer. This 
could be achieved by the use of crutches, a wheel- 
chair, an orthotic shoe, or whatever method the 
investigator determined to be appropriate depending 
on the patient and the location of the ulcer. 
Evaluation of  treatment. Patients were assessed 
weekly for 1 month and thereafter every 2 weeks until 
completion of the 20-week treatment period or until 
100% wound closure occurred. At each visit the 
target ulcer was assessed, by naked eye, according to 
the following functional assessment grade scores: 
1 = 100% wound closure, no drainage present, and 
no dressing necessary; 2 = 100% wound closure, has 
drainage, and dressing required; and 3 = less than 
100% wound closure, has drainage, and dressing 
required. 
Patient compliance was evaluated by means of the 
pretreatment and posttreatment determination of 
tube weights at each visit. Patients or their care givers 
were given diary cards on which to record the 
frequency of dressing changes. Adverse events were 
recorded at each visit. 
Complete healing was defined as the achievement 
of i00% wound closure with no drainage present, 
and no dressing required (ftmctional assessment 
score of 1) and was the primary end point. The time 
to achieve complete wound closure and the percent 
reduction in area of target ulcers were also deter- 
mined and considered as secondary end points. The 
percent reduction in target ulcer area was calculated 
as ([area at baseline - current area]/area t base- 
fine) x 100. 
Responsibility for the conduct of the trial and all 
analyses were undertaken by RW Johnson Pharma- 
ceutical Research Institute. 
Statistical analyses. All randomized patients 
were included in the efficacy and safety analyses. The 
proportion of patients with complete wound healing 
in each treatment group was compared by logistic 
regression, with factors of treatment, center, and 
treatment-by-center interaction with baseline area as 
a covariate. The time to achieve complete wound 
closure was estimated according to fife-table mcthods 
and tested with a log rank test. Because of the 
variation in target ulcer areas, nonparametric tests 
(i.e., a rank transformation) were used to analyze the 
wound area data. The rank target ulcer areas at end 
point in the two treatment groups were compared by 
a two-way analysis of covariance, with factors of 
treatment, center, and their interaction with rank 
baseline area as a covariate. All tests were two sided 
at a significance level of 0.05 and all computations 
were performed with the SAS software package. 13 
To investigate the time profile of therapeutic 
effects, the percentage of patients achieving 100% 
wound closure was computed for each visit up to 
week 20 of therapy. The percent reduction in target 
ulcer area from baseline to each visit up to week 20 
of therapy was also computed. In these computa- 
tions, data of patients who completed the study early 
or missed visits were extended for each subsequent 
week up to week 20. 
RESULTS 
A total of  118 patients were entered from 10 
centers. Five of the centers enrolled between 10 and 
36 patients each. The other five centers enrolled only 
limited numbers of patients (between four and seven 
each), which were not sufficient to show whether 
there was any center bias. Data from these five smaller 
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Table I. Baseline characteristics of patients in the study 
Placebo (n = 57) rhPDGF-BB (n = 61) 
Sex (n) (M/F) 46/i1 43/18 
Race or ethnic group (n) (white/other) 49/8 53/8 
Age (yr) (mean) 58.3 63.2 
tcPO2 at wound edge (mm Hg) 
n 17 15 
Mean 58.9 45.7 
tcPO2 at foot dorsum (ram Hg) 
n 40 46 
Mean 59.7 58.6 
Time since ulcer onset (wk) 
Mean 74.5 81.8 
Range 6.7-349.6 6.6-536.0 
tcP02, Transcutaneous oxygen pressure. 
Table II. Baseline target ulcer areas 
Placebo rhPDGF-BB 
n 57 ~ 61 
Target ulcer area (crn 2) 
Range 0.6-111.2 0.2-57.4 
Mean 9.0 5.5 
Median 4.9 3.i 
Mean depth (cm) 0.65 0.64 
Target ulcer size ranges (n) 
< 2.4 cm 2 15 23 
2.4-5.7 cm 2 18 20 
> 5.7 cm 2 24 18 
*One patient was a significant outlier. Excluding this patient from the target ulcer area measurements resulted in the following changes: 
range = 0.6 to 35.8 cm 2, mean = 7.2 cm 2, and median = 4.7 cm 2. 
centers were pooled to determine center interaction 
data. No center bias was observed for the five larger 
centers or the pooled data for the five smaller centers. 
Sixty-one patients (43 men and 18 women) were 
randomized to receive rhPDGF-BB and 57 patients 
(46 men and 11 women) were randomized to receive 
placebo. There were no statistically significant dif-
ferences between the two groups with respect to sex 
and race, duration of ulcer, area of ulcer, and 
transcutaneous partial pressure of oxygen at the 
dorsum and wound edge (Table I). Patients treated 
with rhPDGF-BB were on average 5 years older 
than patients treated with placebo. Although this 
difference was statistically significant (p = 0.02), it 
is not considered clinically significant. 
Baseline target ulcer areas are shown in Table II. 
Thirteen patients had target ulcers that were smaller 
than 1 cm 2. One patient aking placebo had a target 
ulcer of 111 cm 2. All other patients met the inclusion 
criteria with target ulcers in the range of 1 to 100 cm 2. 
Fourteen (23%) of the 61 rhPDGF-BB-treated 
patients and 18 (31.6%) of the 57 placebo-treated 
patients discontinued the study before completing 20 
weeks of treatment. Table III lists the specific reasons 
for discontinuation. 
The percentage of patients in both groups who 
demonstrated complete wound healing (functional 
assessment score grade 1) during the trial is shown in 
Fig. 1. A greater proportion of rhPDGF-BB-treated 
patients achieved complete wound healing than did 
placebo-treated patients during the course of the 
study (p = 0.01). The difference in healing rates 
began to emerge after approximately 6 weeks of 
therapy and remained uniform throughout the 
remainder of the study. During the 20-week 
study period, 29 (48%) of the 61 patients treated 
with rhPDGF-BB achieved complete wound healing 
(functional assessment score 1) compared with only 
14 (25%) of the 57 patients treated with placebo 
(2o = 0.01). One patient (placebo) completed the 
study with a functional assessment score of 2. 
An analysis of interaction between center and 
treatment was carried out. In each of the six centers 
(the five larger independent centers and the pooled 
data for the five smaller centers), agreater number of 
rhPDGF-BB-treated patients demonstrated corn- 
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Fig. 1. Percentage of patients with complete wound closure. Cummulative summary of 
percentage of patients achieving complete wound closure during 20-week study period. 
plete healing than did placebo-treated patients, and 
there was no significant interaction between center 
and treatment (p = 0.88). 
The median percent reduction in wound area over 
time for both groups is illustrated in Fig. 2. There was 
a greater eduction in wound size in the rhPDGF- 
BB-treated group than i  the placebo-treated group 
during the study, and this difference b came vident 
after 3 weeks of treatment and was maintained 
throughout the rest of the trial. The median percent- 
age reduction in wound area in the rhPDGF-BB- 
treated group was 98.8% compared with 82.1% in 
the placebo-treated group. The treatment effect was 
marginally significant in the analysis of the rank end 
point area (p = 0.09). In addition, wounds healed 
more quickly in the rhPDGF-BB-treated group. 
From approximately day 68 to the end of the trial, 
a difference of 30 to 40 days in the time to com- 
plete wound healing was observed between the 
rhPDGF-BB and placebo groups (p = 0.01). 
There was no statistical difference in the number 
of debridements carried out in the two treatment 
groups, On average a patient underwent debride- 
ment on 47.4% of the study visits in the pla- 
cebo group and 43.3% of the study visits in the 
rhPDGF-BB group. There was a possibility that there 
may have been a center effect on the number of de- 
bridements carried out and this may have affected the 
rate of ulcer healing. However, neither the treatment 
nor treatment-by-center interaction showed any sta- 
tistically significant differences in the number or per- 
centage of visits during which debridement occurred 
(p > 0.2). 
Recurrence of the target ulcer was assessed in 
those patients who demonstrated complete wound 
healing during the study. There was a trend toward 
a greater recurrence rate in the placebo group than in 
the rhPDGF-BB group, although this did not reach 
statistical significance. In the placebo group, 46% of 
the originally healed target ulcers recurred at a mean 
time of 8.5 weeks, whereas in the rhPDGF-BB group 
only 26% of target ulcers recurred at a mean of 8.6 
weeks .  
The incidence of adverse vents reported uring 
the trial was not significantly different for the two 
groups. Thirty-one (51%) of 61 rhPDGF-BB-treated 
patients and 34 (60%) of 57 placebo-treated patients 
reported at least one adverse vent. Ten (16% ) of 61 
rhPDGF-BB-treated patients and 10 (18%) of 57 
placebo-treated patients reported having at least one 
adverse vent, considered by the investigator to have 
a possible, probable, definite, or unknown relation- 
ship to the study medication. Table IV summarizes 
the incidence of adverse vents for those events that 
occurred in at least 5% of patients in either treatment 
group. Most adverse vents were mild to moderate 
and transient. The overall incidence of wound-related 
infections, including cellulitis, wound infection, and 
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Fig. 2. Median reduction in wound area of target ulcer 
during course of study. Observations are carried forward 
for patients who did not complete 20 weeks of treatment 
or missed visits. 
osteomyelitis, was 26.3% for placebo-treated and 
i 1.4% for rhPDGF-BB-treated groups, respectively. 
DISCUSSION 
Neurotrophic ulcers of the foot are a common 
problem in patients with long-standing diabetes 
mellitus. These ulcers heal slowly because of repeated 
trauma from weight bearing, peripheral neuropathy 
caused by the diabetes, and, in many cases, reduced 
arterial blood flow because of peripheral vascular 
disease) Chronic nonhealing ulcers occur in as many 
as 10% of patients with diabetes. The successful 
treatment of diabetic neurotrophic ulcers includes 
appropriate selection of at-risk patients and careful 
management of the wounds. We selected patients 
with transcutaneous partial pressure of oxygen of 30 
mm Hg or greater to ensure that arterial circulation 
was adequate, t4-t6 Measurement of ankle/brachial 
index alone is not satisfactory for determining 
perfusion of the ulcerated region, because patients 
with diabetes often have severely calcified arteries that 
are poorly compressible. Thus the Doppler-derived 
arterial blood pressure may be falsely elevated, 
leading to an elevated ankle/brachial index. 
Other factors that may affect wound healing were 
also investigated before initiation of the study to 
ensure that these did not differ between the 
rhPDGF-BB and placebo groups. No patients were 
included who had active infection until the infection 
had been eradicated. All wounds were debrided 
down to normal tissue so that callus and infected and 
necrotic tissue were removed before randomization. 
Patients were instructed not to bear weight on the 
wounds. Although this aspect of the study was 
difficult to assess, only patients who agreed to be 
non-weight bearing were admitted to the trial. 
In this study we assessed the ability of a single 
growth factor (rhPDGF-BB) to promote wound 
healing. We selected the rhPDGF-BB dose of 2.2 
~g/cm 2ulcer area applied daily based on the results 
of preclinical dose-response tudies. 17 Our results 
show that a significantly greater number of patients 
treated with rhPDGF-BB demonstrated complete 
wound closure during the course of the 20-week 
study compared with patients treated with placebo. 
In addition, in patients whose wounds healed uring 
the study, wounds healed significantly more quickly 
when treated with rhPDGF-BB. For all randomized 
patients, rhPDGF-BB-treated wounds showed a 
trend toward a greater reduction in wound area 
during the study than did placebo-treated wounds, 
although this did not reach statistical significance. It 
is difficult to determine the clinical significance of 
achieving a reduction in area of target ulcer during 
the study. However, the complete wound healing 
rate in the rhPDGF-BB group (48%) was twice that 
for the placebo group (25%), and the significance of 
this to the patient is more obvious. There was no 
significant difference in the incidence of adverse 
events in patients treated with rhPDGF-BB or 
placebo gel. 
There was a tendency for a lower recurrence rate 
in the rhPDGF-BB group than in the placebo group. 
Although this did not reach statistical significance, it 
suggests that rhPDGF-BB-healed wounds are at least 
as durable as control-healed wounds. 
It has been reported that simian sarcoma virus can 
transform various PDGF-responsive cell types, in- 
cluding human fibroblasts and bovine smooth muscle 
cells, allowing these cells to grow in soft agar and in 
focus formation in monolayer.~8 The transformations 
induced by the simian sarcoma virus are thought o 
be mediated through a PDGF-like molecule, and 
there is a theoretic possibility that PDGF may lead to 
transformations it elf. In addition, some ccUs derived 
from human tumors, including hepatomas, bladder 
cancers, and colon carcinomas, can be stimulated to 
synthesize PDGF. 6 Some transformed cells produce 
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Table II I .  Primary reasons for discontinuation from the study 
Placebo (n) (n = 57) rhPDGF-BB (n) (n = 61) 
Adverse xperience 6 6 
Treatment failure 5 3 
Noncompliance 1 1 
Intercurrent medical problem 2 2 
Lost to follow-up 1 2 
Patient death 2 0 
Other 1 0 
Total discontinuations I8 (31.6%) 14 (23.0%) 
Total completing study 39 (68.4%) 47 (77.0%) 
Table IV. Adverse events occurring in greater than 5% of patients 
No. of patients with event (%) 
Placebo (n = 57) rhPDGF-BB (n = 61) 
Infection 9 (16) 7 (11) 
CeUulitis 7 (12) 3 (5) 
Peripheral edema 7 (12) 4 (7) 
Pneumonia and upper RTI 7 (12) 1 (2) 
Pain 6 (11) 4 (7) 
Skin ulceration 5 (9) 5 (8) 
Influenza-like symptoms 3 (5) 1 (2) 
Myocardial infarction 3 (5) 0 
RT/, Respiratory tract infection. 
PDGF that can bind to receptors on their own 
surface, inducing rumor expansion, whereas other 
cells do not have PDGF receptors but secrete PDGF 
that binds to receptors on connective cells in the 
tumor environment. Thus PDGF may be involved in 
tumor proliferation and inducing responses in the 
tissue environment adjacent o tumors. 6 However, 
there is no evidence that PDGF is capable of 
transforming cells when added exogenously. 19 More- 
over, the ability of rhPDGF-BB to affect tumor 
growth may be minimized by the poor absorption 
into the systemic irculation after topical application. 
There are few reports in the literature of the use of 
PDGF to stimulate healing of chronic diabetic ulcers. 
However, several authors have investigated a prepa- 
ration obtained from isolated platelets, known as 
platelet-derived wound-healing formula (PDWHF), 
in this context. PDWHF contains a mixture of 
growth factors, including PDGF, transforming 
growth factor-J3, EGF, and platelet-derived angio- 
genesis factor. PDWHF is not the same as the recom- 
binant rhPDGF-BB used in this study and, therefore, 
the results cannot be extrapolated to currently mar- 
keted PDWItF products. Knighton et al. 2~ were the 
first to report initiation of wound healing after once- 
daily administration f PDVVHF to a variety of differ- 
ent wounds of the lower extremity including diabetic 
neurotrophic ulcers. 2°,21 Similar success was reported 
by Atri et al., 22 who treated a variety of lower ex- 
tremity wounds with an autologous preparation of 
PDWHF. Krupski et al., 2~ however, found a ho- 
mologous preparation of PDWHF to provide no ad- 
ditional benefit over standard therapy in the treat- 
ment of lower extremity ulcers. 
There are four published studies of use of 
recombinant growth factors to treat chronic wounds 
in humans. Brown et ill. 24 published an uncontrolled 
study in various types of chronic wounds and 
concluded that topically applied rhEGF may be 
beneficial to healing. Falanga et al. 2~ published a 
study that described the use of rhEGF in a single- 
center, double-blind, placebo-controlled study to 
treat 44 patients with chronic venous ulceration of 
the lower extremity. Although numeric trends were 
demonstrated favoring the recombinant product, 
statistical significance was not achieved. A study by 
Robson et al.n has demonstrated the effectiveness of
recombinant rhPDGF-BB on the healing of chronic 
pressure ulcers. Although Robson et al. concluded 
that rhPDGF-BB was superior to placebo in their 
study, the results were based on a 28-day model in 
which the ulcers were not followed up to complete 
closure. Finally, in a study by Mustoe et al.,12 it was 
shown that rhPDGF-BB was effective in reducing the 
size of chronic, full-thickness pressure ulcers com- 
pared with placebo. Ulcers were followed up for only 
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29 days and, therefore, an effect of rhPDGF-BB on 
complete wound closure was not demonstrated. 
In the study reported here, both the placebo and 
rhPDGF-BB groups received what could be consid- 
ered as "best standard wound care" in addition to the 
application of study gel. In all randomized patients, 
wounds were surgically debrided at study entry and 
further debridements were permitted if necessary, 
and systemic antibiotics were given to treat infections 
if they occurred during the study. Each patient 
received instructions for pressure relief of the target 
ulcer, and topical application of any other medication 
to the target ulcer, apart from study gel, was avoided. 
The limitation of our study to a 20-week treat- 
ment period does not allow determination of the 
maximum achievable rates of healing. Further studies 
are needed to assess the efficacy and safety of 
rhPDGF-BB in other types of nonhealing wounds 
and to address the cost-effectiveness compared with 
standard care. We showed that there is a subgroup of 
rhPDGF-BB-treated patients who do not respond to 
the rhPDGF-BB regimen employed in this trial. 
Further work needs to be performed to characterize 
this subgroup. Variables that were shown not to have 
an effect on wound healing include target ulcer area 
and depth at baseline, age of target ulcer, age of 
patient, transcutaneous oxygen tension, and hemo- 
globin Aic levels. 
This randomized, prospective, double-blind, pla- 
cebo-controlled, parallel-group, multicenter trial 
demonstrated that repeated, once-daily, topical ap- 
plication of rhPDGF-BB is safe and stimulates rapid 
heating of chronic, full-thickness neurottophic ul- 
cers of the lower extremity in patients with dia- 
betes mellitus. This is the first well-controlled trial 
to demonstrate a statistically significant difference 
in both the number of patients healed and the heal- 
ing rates in diabetic patients with chronic wounds 
treated topically with a recombinant growth factor. 
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APPENDIX:  D IABET IC  ULCER 
STUDY GROUP 
Study Group:  Marshal l  W. Webster,  MD,  
University of Pittsburgh School of Medicine, 
Pittsburgh, Pa.; John J. Ricotta, MD,  State 
University of New York at Buffalo, Buffalo, N.Y.; 
Arnold Luterman,  MD,  University of South 
Alabama Medical Center, Mobile, Ala.; Spencer 
Brown, MD,  the Diabetes Management  and Re- 
search Center, Los Angeles, Calif.; Anthony J. 
Comerota, MD, Temple University Hospital ,  
Philadelphia, Pa.; Daniel B. Walsh, MD,  
Dartmouth-Hitchcock Medical Center, Hanover, 
N.H. ;  Thomas M. Bergamini,  MD,  Veterans 
Administrat ion Medical Center, Louisville, Ky.; 
Wil l iam H.  Baker, MD,  Loyola University Medi- 
cal Center, Maywood, Ill.; Robert S. Boltax, MD,  
Hospital of St. Raphael, New Haven, Conn.; 
Thomas H. Schwarcz, MD, University of Ken- 
tucky Medical Center, Lexington, Ky.; Dennis J. 
Donohoe, MD, and Allen Fleishman, PhD,  RW 
Johnson Pharmaceutical Research Institute, Rari- 
tan, N.J. 
DISCUSSION 
Dr. William C. Krupsld (Denver, Colo.). You have 
shown that topical application f recombinant human 
platelet-derived growth factor (PDGF) to chronic lower 
extremity neurotrophic ulcers in diabetic patients with 
normal circulation resulted in a twofold improvement in 
the rate of complete healing compared with control 
subjects. This is the first large well-controlled study to 
demonstrate a statistically significant difference in both the 
number of wounds healed and the wound-healing rates in 
diabetic patients with any topical growth factor. Moreover, 
in contrast to some previously published work, this is truly 
a multicenter trial conducted by respected investiga- 
tors, none of whom had any financial interest in this 
product. 
Currently there are more than 30 trials of various 
growth factors approved by the U.S. Food and Drug 
Administration, and many are being directed by private 
industry. The potential market for these agents is esti- 
mated at billions of dollars. There is too much at stake 
to accept anything less than completely independent 
investigations. 
The most widely studied agent for facilitating healing 
of chronic wounds in humans is a conglomeration of
growth factors and other compounds found in platelets 
called platelet-derived wound healing factors, currently 
marketed as Procuren. The material is obtained by pro- 
cessing the patient's own platelets and is not regulated by 
the Food and Drug Administration. We performed a
controlled, randomized, blinded, preliminary trial of Pro- 
curen in 18 patients with 26 heterogeneous lower extremity 
wounds refractory to conventional therapy and found that 
the rate of healing of Procuren-treated patients was no 
better than that of placebo-treated patients. 
Do you think one can extrapolate the results of your 
well-performed study of recombinant PDGF to suggest 
that Procuren is equally effective? Second, all patients in 
your study had normal transcutaneous oxygen pressure, a 
different population than is seen by most vascular surgeons 
who deal with patients with vascular diseases. Do you 
suppose that PDGF will also be effective in patients with 
both diabetes and vascular insufficiency, which so often 
coexist? 
Third, whereas the median reduction of PDGF-treated 
wounds was 98% after 20 weeks, the median reduction in 
control wounds was 82%, a difference of only 16%. Does 
the statistically significant improvement in healing corre- 
spond to a significant clinical difference? 
Fourth, center bias is always a possibility in multicenter 
trials. In your study the number of patients treated ranged 
from four at two small centers to 36 at your own institution 
in Pittsburgh. Were all variables analyzed by the center and, 
if so, did results favor PDGF in the majority of centers? 
Fifth, last year at these same meetings you presented 
data indicating a high recurrence rate of neurotrophic 
diabetic foot ulcers. Do you have any information about 
the durability and long-term outcome of the wounds 
healed with PDGF? 
Finally, in this cost-conscious era, although recombi- 
nant DNA technology is readily available, it is not cheap. 
I called our pharmacy to ascertain the cost to the patient for 
one vial or dose of the following recombinant products: 
recombinant granulocyte colony-stimulating factor, cost 
$338; recombinant human growth hormone, $1962; and 
recombinant tissue plasminogen activator, $2022. Do you 
know how expensive PDGF will be for a 20-week 
treatment? Although we all aspire to achieve more rapid 
wound healing, will it be worth the thousands of dollars 
that this product will likely cost to produce healing that is 
16% more rapid? 
Dr. David L. Steed. Can we extrapolate hese results 
to Procuren? I believe the answer is no. We used a single 
growth factor here, PDGF, whereas Procuren is a platelet 
releasate containing multiple growth factors. I do not know 
the concentration fPDGF in that preparation. I believe it 
is likely that a single growth factor will work a bit 
differently than a platelet releasate. ][ do have a concern that 
if you use a platelet releasate not all growth factors timulate 
healing. Some might be inhibitory. That may be why, for 
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example, patients have keloids: they do not exert the 
inhibitory factors as healing ends. If you concentrate the 
platelet releasate, it is difficult o know wha t you are doing 
with those inhibitory factors, and I do not believe our data 
can be extrapolated to Procuren. 
Will PDGF be effective in vascular insufficiency? We 
studied only patients we thought had an adequate blood 
supply. The literature would suggest that as many as 60% 
to 70% of patients with diabetic ulcers have neuropathy as 
a cause and a normal blood supply. If  we have a patient we 
believe has vascular insufficiency, we perform a bypass. 
You had a question that the difference in median 
healing was only I6% and is that significant. I do not 
believe that a wound that is 98% healed is much better than 
a wound that is 82% healed, because both of those wounds 
still require dressings and visits to the physician, there is still 
a possibility of infection, they still have to be non-weight 
bearing, and they still cannot return to work. The primary 
end point here was complete healing, and the complete 
healing rate was nearly doubled. I believe if you are going 
to evaluate foot ulcers in diabetic patients in a growth factor 
trial, you should look at complete healing. It is interesting 
to look at the percent healed, but I do not think that is the 
primary end point of this study, and that is not how we 
designed it. 
With regard to variables analyzed by center, we had five 
centers with more than 10 patients, and we had five centers 
with fewer than 10 patients. In the ones with fewer than 10 
patients, it is difficult o say whether there was a center bias, 
but if you combine those five centers with fewer than 10 
patients and consider that one group, and the other five 
centers, you have six groups to analyze, and the data went 
in the same direction in all six of those centers. 
With regard to the recurrence rate of ulcers, I do not 
have those data, but we have now had a chance to follow 
these patients about 1 year and the recurrence rate may be 
as high as 25%. The one thing I have noted is that, similar 
to the data reported last year, if your ulcer is going to break 
down, it usually breaks down early within the first 2 
months. That suggests that if a patient can learn to be 
compliant and wear special footwear, he or she learns early, 
and if it can be done early, the ulcer stays healed. It is 
possible that the healing is not durable, but that remains to 
be shown. 
What is the cost? I do not know what PDGF is going 
to cost when it comes to market, if it comes to market. The 
patients who were treated with PDGF in this trial received 
PDGF at no cost. There is no question that recombinant 
DNA technology is expensive, but so are dressings, 
amputations, and prosthetic limbs. If this product is going 
to be brought o market, the burden of proof will be on the 
sponsor who brings it to market to show that it is 
cost-effective, and in these days when we look at health care 
dollars, and they are tight, I believe it is not enough to say 
something is working. If you want to bring it to market, 
you will have to show that it is cost-effective, and that will 
be up to someone lse to do that. 
Dr. Martin E. Harr ington (New York, N.Y.). Work- 
ers in our institution had noted that about 60% of bland 
diabetic ulcers had osteomyelitis when studied with bone 
biopsy and culture. In your patients, noting that 50% to 
75% of them did not heal, were they not worked up well 
enough to look for osteomyelitis? What happened to the 
ones who were judged to be infected? Was healing of the 
ulcers affected by whether the patients received antibi- 
otics? 
Dr. Steed. The question is osteomyelitis and how 
many had it. The incidence of infection was 7% in both 
groups, and that included both osteomyelitis and cellulitis. 
When we debrided them all initially, if we came down to 
bone and it was involved, we debrided it. No patient could 
be entered until we thought he or she was free of 
osteomyelitis. If  they were debrided own to bone, they 
could be entered once the bone was covered. 
Dr. Gary Gibbons (Boston , Mass.) If  you look at the 
late Roger Pecoraro's work and our own work, 50% of 
nonhealing ulcers may actually be complicated by ischemia. 
I am not sure that just going by transcutaneous oxygen 
pressure isadequate to rule out ischemia s a component of 
nonhealing ulceration, especially in the duration of the 
ulcers that your group was dealing with. 
The other is durability, and is that not what we are 
really talking about? You are taking patients who have 
already spent 20 weeks of their lives with an ulcer, and now 
you are following up these patients for another 20 weeks of 
non-weightbearing. Both of the slides you showed were 
plantar ulcers, one under the first metatarsal nd one under 
the third metatarsal; would not an alternative form of 
treatment have been to do an osteotomy on the one 
underneath t e third metatarsal nd a metatarsophalangeal 
joint resection underneath the first? Is it not the bony 
prominence that gets the patient into trouble to begin 
with? By working as a team with your podiatrist or 
orthopedic group, and getting rid of that ulcerated bony 
prominence, we have achieved early and lasting healing in 
more than 90% of these patients. This is an alternative form 
of treatment, rather than waiting 100 weeks for local 
treatment and accepting a higher recurrence rate. 
Dr. Steed. I agree with what you say. The transcuta- 
neous oxygen pressure may not be adequate to rule out 
ischemia. It is difficult to know how to rule out ischemia. 
If you use ankle/brachial index, the values may be falsely 
elevated, so you have to try to define ischemia in some other 
manner. We used the transcutaneous oxygen tension, 
measured on the dorsum of the foot and not at the ulcer 
margin, believing that would at least be some measure to 
suggest that the blood supply was adequate. I emphasize 
that we perform bypass in patients who are thought o have 
ischemic ulcers. The patients who have adequate blood 
supply go into these studies. Certainly, if you look at the 
literature, there are many patients who have normal blood 
supply and ulcers related to neuropathy. I went back and 
looked at 200 patients with diabetic foot ulcers that we had 
seen in our clinic. Sixty-eight percent had a palpable pulse 
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and were thought o have a normal blood supply. Of course 
the patients we see reflect he types of patients who were 
referred to us. 
In terms of why not resect he bony prominence, I 
agree that that certainly is an acceptable form of therapy, 
and some of these patients had undergone that procedure 
and the wounds did not heal. These ulcers had been present 
for nearly llA years; 70 to 80 weeks was the mean duration 
of these ulcers before healing and they still were not healed. 
When we debrided them, if we came down to the bone, we 
debrided the metatarsal head and allowed that patient o 
enter only once that had been granulated. I agree that that 
is an accepted form of therapy and, in many cases, may be 
adequate. 
I do not believe it is unreasonable to have several 
centers look at new therapies. Despite the best treatments, 
10% of patients with diabetic ulcers have ulcers that do not 
heal. If you consider the fact that there are between 11 and 
16 million diabetic patients in the United States and 10% 
will get a foot ulcer, there are one to one and a half million 
patients with foot ulcers. Because 10% still do not heal, 
there may be a role for a therapy such as this. I agree with 
your comments. 
Dr. Frank LoGerfo (Boston, Mass.). As you know, we 
have a strong interest in this problem. There was one thing 
that bothered me: the size of the ulcers in the placebo group 
was larger. Now I understand that it was not statistically 
significant, but it could be significant in your outcome. 
Now think about this: You have an ulcer that is 100 cm 2, 
and you have 10 cm 2 of healing. That is 10% healed. If you 
have 10 ulcers and each one is 1 cm, you have the same 
amount of healing, but they are all completely healed. So 
I think there is a possibility that even though the size 
difference in terms of median and mean is not significant, 
when it comes to your outcome measure, it could explain 
why you get more healed ulcers in your treatment group 
and fewer healed ulcers in your placebo group; however, 
when it comes to the relative amount of healing, there is no 
difference. I think that something needs to be looked at 
very critically. I would like to echo the comments about 
durability, because it cannot be emphasized too much. 
These are neuropathic ulcers. If  you take the patient offthe 
foot, it is going to heal. Our mission, however, is to get the 
patients on their feet; again, I do not mean to be repetitious 
but we do not want to spend thousands and thousands of 
dollars to have this recur. 
Dr. Steed. In terms of the ulcers treated with placebo 
being larger, there is no question that that occurred, and we 
reported that. As you do a blinded clinical study and you 
randomize the patients, you do not know who gets what 
until the end of the trial and you go back to look at the data. 
That is what happens when you enter 118 patients; you 
may find that your ulcer sizes are not the same. There is no 
question that the placebo group was larger but the data 
were somewhat skewed by one outlier. 
We have tried to look at not only complete healing but 
percent area healed, and the percent area healed favored the 
PDGF, although the p value was 0.06. What you say is 
correct, and I do not know any way to avoid that when you 
are doing clinical trials and randomizing patients. 
In terms of the durability, again it has been bothersome 
for us that a quarter of these ulcers are going to recur. I do 
believe that part of it is patient compliance, and we have 
been trying to do things like fit patients with special shoes 
with inserts to alleviate the pressure points, and we will wait 
to see if that helps. 
